immunotherapy

December 20, 2018
Richard L. Schilsky, MD, FACP, FSCT, FASCO

Tumor-Agnostic Treatment for Cancer: An Expert Perspective

English
Richard.Schilsky

Some recent FDA approvals have made many people aware of tumor-agnostic treatments. But what does that mean and how could it benefit someone with cancer? ASCO Chief Medical Officer Richard L. Schilsky gives insight into this new way of thinking about cancer treatment.

Read More >>
2018 ASCO Annual Meeting; #ASCO18
June 3, 2018
Monika Sharda, ASCO staff

ASCO Annual Meeting 2018: Less Treatment Needed for Some Patients With Breast Cancer and Kidney Cancer, Immunotherapy for Non-Small Cell Lung Cancer, and Maintenance Chemotherapy for Rhabdomyosarcoma

English
Monika.Sharda

Oncology professionals from around the globe are at the 2018 ASCO Annual Meeting. Today’s key research highlights include new treatment options and improved survival for breast cancer, kidney cancer, non-small cell lung cancer, and rhabdomyosarcoma.

Read More >>

Pages

Subscribe to RSS - immunotherapy